Which is the foreseeable clinical application of oxygen-carrying blood substitutes (fluorocarbons and hemoglobin solutions)? Which impact are they likely to have on the activity of blood services?
D000740:Anemia / Q000628:therapy; D000818:Animals; D001692:Biological Transport; D001771:Blood Banks; D001782:Blood Donors; D001802:Blood Substitutes / Q000009:adverse effects / Q000627:therapeutic use*; D004285:Dogs; D004338:Drug Combinations / Q000627:therapeutic use; D005466:Fluorocarbons / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism / Q000502:physiology*; D006470:Hemorrhage / Q000628:therapy; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives; D012157:Mononuclear Phagocyte System / Q000187:drug effects; D010100:Oxygen / Q000502:physiology*; D012068:Religion and Medicine; D012996:Solutions
D001802:Blood Substitutes; D004338:Drug Combinations; D005466:Fluorocarbons; D006454:Hemoglobins; D006895:Hydroxyethyl Starch Derivatives; D012996:Solutions; C017323:glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination; D010100:Oxygen